Miramar, Florida, August 5, 2026
Aveva Drug Delivery Systems, Inc., a DifGen Pharmaceuticals company, has secured a significant legal and commercial milestone after the U.S. Court of Appeals for the Federal Circuit affirmed a lower court ruling that Aveva’s proposed generic lidocaine topical system 1.8% does not infringe patents associated with Scilex Pharmaceuticals’ ZTlido® product. The decision removes a major patent-related obstacle as Aveva prepares for the imminent commercial launch of its generic lidocaine topical system with 180-day exclusivity. According to the announcement, the Federal Circuit upheld the finding that Aveva’s proposed generic does not infringe U.S. Patent Nos. 9,283,174, 9,925,264 and 9,931,403, either literally or under the doctrine of equivalents. The development is particularly important for the competitive generic pharmaceutical market, where patent litigation following an Abbreviated New Drug Application (ANDA) and Paragraph IV certification can significantly influence the timing of market entry.
Federal Circuit Affirms Non-Infringement Decision
The patent dispute originated in June 2022, after Aveva submitted an ANDA containing a Paragraph IV certification challenging patents listed for ZTlido®, a lidocaine topical system 1.8%. Scilex Pharmaceuticals, ITOCHU Chemical Frontier Corp. and Oishi Koseido Co., Ltd. subsequently brought litigation against Aveva in the U.S. District Court for the Southern District of Florida. Following a bench trial in July 2024, the district court concluded that Aveva’s proposed generic product did not infringe the patents at issue and awarded Scilex no damages or injunctive relief. Scilex appealed the decision to the Federal Circuit in March 2025. The appellate court has now affirmed the district court’s non-infringement determination, providing Aveva with greater certainty regarding its planned generic commercialization. The outcome represents a notable development at the intersection of pharmaceutical intellectual property, generic drug competition and regulatory strategy, particularly for companies pursuing difficult-to-develop drug delivery products through the ANDA pathway.
Aveva Prepares Generic Lidocaine System for Commercial Launch
Following the appellate ruling, Aveva said the path is clear for it to move toward the commercial launch of its generic lidocaine topical system 1.8%, which the company states will benefit from 180-day exclusivity. Such exclusivity can be commercially important in the U.S. generic pharmaceutical market by providing an eligible first generic applicant with a limited period of competitive advantage under applicable regulatory provisions. Aveva specializes in the development and manufacturing of transdermal delivery systems, oral dissolvable films and sterile pharmaceutical products, giving the company manufacturing capabilities relevant to complex and specialized dosage forms. Its facilities in Miramar, Florida, span four sites totaling approximately 210,000 square feet, supporting manufacturing, packaging and marketing of prescription and over-the-counter transdermal and oral film products. The company also maintains capabilities for handling certain controlled substances.
Advertisement
Patent Victory Strengthens DifGen’s Complex Generics Strategy
The ruling also supports the broader strategy of DifGen Pharmaceuticals, which focuses on complex, high-barrier-to-entry generic and specialty pharmaceutical products. Complex generics can require specialized formulation, manufacturing, regulatory and drug-delivery expertise, creating additional technical challenges compared with conventional oral generic medicines. Aveva’s experience in transdermal drug delivery systems aligns with DifGen’s strategy of developing differentiated dosage forms across therapeutic areas. The Federal Circuit decision does not represent a new drug approval; rather, it resolves the patent infringement issue described in the litigation and enables Aveva to proceed with its stated commercialization plans. Nevertheless, the combination of ANDA development, Paragraph IV patent litigation, 180-day exclusivity and planned generic market entry makes the development significant for the U.S. pharmaceutical sector. As Aveva moves toward launch, the generic lidocaine topical system could strengthen DifGen’s presence in specialized generic medicines while highlighting the growing role of technically complex drug-delivery products in pharmaceutical competition.
Source: Aveva Drug Delivery Systems, DifGen Pharmaceuticals press release
